Takeaways: XORTX’s planned Canadian CTA could strengthen XORLO’s regulatory pathway while generating clinical evidence to support a future U.S. NDA. The proprietary oxypurinol formulation ...
Browsing Tag: XRx-026
Takeaways: XORTX’s planned Canadian CTA could strengthen XORLO’s regulatory pathway while generating clinical evidence to support a future U.S. NDA. The proprietary oxypurinol formulation ...